About Devyser
Devyser is a company based in Stockholm (Sweden) founded in 2004.. Devyser has raised $15.48 million across 2 funding rounds from investors including Swedbank Robur and Fjarde AP-fonden. The company has 132 employees as of December 31, 2024. Devyser has completed 1 acquisition, including SmartSeq. Devyser offers products and services including Devyser BRCA NGS, Devyser Chimerism NGS, Devyser Thalassemia NGS, and Devyser RHD. Devyser operates in a competitive market with competitors including Abcam, ArcherDX, Stem Cell Technologies, GenScript and Sino Biological, among others.
- Headquarter Stockholm, Sweden
- Employees 132 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Devyser Diagnostics Ab
-
Annual Revenue
$19.66 M (USD)28.12as on Dec 31, 2024
-
Net Profit
$-5.58 M (USD)-14.74as on Dec 31, 2024
-
EBITDA
$-3.68 M (USD)13.06as on Dec 31, 2024
-
Total Equity Funding
$15.48 M (USD)
in 2 rounds
-
Latest Funding Round
$15.48 M (USD), Series B
Feb 02, 2021
-
Investors
Swedbank Robur
& 1 more
-
Employee Count
132
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Devyser
Devyser is a publicly listed company on the OMXSTO with ticker symbol DVYSR in Sweden, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Devyser
Devyser offers a comprehensive portfolio of products and services, including Devyser BRCA NGS, Devyser Chimerism NGS, Devyser Thalassemia NGS, and Devyser RHD. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Detects mutations in BRCA1 and BRCA2 for cancer diagnostics
Monitors chimerism in transplant patients accurately
Performs comprehensive testing for thalassemia disorders
Screens for fetal RHD in non-invasive prenatal testing
Unlock access to complete
Funding Insights of Devyser
Devyser has successfully raised a total of $15.48M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $15.48 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $15.5M
-
First Round
First Round
(19 Jan 2021)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2021 | Amount | Series B - Devyser | Valuation | Swedbank Robur , Fjarde AP-fonden |
|
| Jan, 2021 | Amount | Grant - Devyser | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Devyser
Devyser has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Swedbank Robur and Fjarde AP-fonden. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Swedbank Robur is recognized as Sweden's largest fund management company.
|
Founded Year | Domain | Location | |
|
Manages Swedish national pension assets with sustainable investment strategies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Devyser
Devyser has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SmartSeq. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Next-generation sequencing data analysis software is provided.
|
2014 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Devyser
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Devyser Comparisons
Competitors of Devyser
Devyser operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, ArcherDX, Stem Cell Technologies, GenScript and Sino Biological, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biological reagents and antibodies are developed for life science research.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Developer of cell culture media and ancillary reagents for life science research
|
|
| domain | founded_year | HQ Location |
Reagents and instruments are provided for life sciences research.
|
|
| domain | founded_year | HQ Location |
Reagents and kits are provided for clinical research applications.
|
|
| domain | founded_year | HQ Location |
Products and reagents for molecular diagnostic assays are supplied.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Devyser
Frequently Asked Questions about Devyser
When was Devyser founded?
Devyser was founded in 2004 and raised its 1st funding round 17 years after it was founded.
Where is Devyser located?
Devyser is headquartered in Stockholm, Sweden.
Is Devyser a funded company?
Devyser is a funded company, having raised a total of $15.48M across 2 funding rounds to date. The company's 1st funding round was a Grant of $905.43K, raised on Jan 19, 2021.
How many employees does Devyser have?
As of Dec 31, 2024, the latest employee count at Devyser is 132.
What is the annual revenue of Devyser?
Annual revenue of Devyser is $19.66M as on Dec 31, 2024.
What does Devyser do?
Devyser was founded in 2004 in Stockholm, Sweden, and operates in the molecular diagnostics sector. Kits based on next-generation sequencing are offered for BRCA 12 characterization, gene panels targeting familial hypercholesterolemia, cystic fibrosis, thrombophilia, hereditary hemochromatosis, and APOE for Alzheimers risk assessment. Additional products include cardiovascular disease tests, QF-PCR for prenatal aneuploidy, and cytogenetic defect assessments.
Who are the top competitors of Devyser?
Devyser's top competitors include Abcam, Sino Biological and Qiagen.
What products or services does Devyser offer?
Devyser offers Devyser BRCA NGS, Devyser Chimerism NGS, Devyser Thalassemia NGS, and Devyser RHD.
Is Devyser publicly traded?
Yes, Devyser is publicly traded on OMXSTO under the ticker symbol DVYSR.
How many acquisitions has Devyser made?
Devyser has made 1 acquisition, including SmartSeq.
Who are Devyser's investors?
Devyser has 2 investors. Key investors include Swedbank Robur, and Fjarde AP-fonden.
What is Devyser's ticker symbol?
The ticker symbol of Devyser is DVYSR on OMXSTO.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.